These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Clinical inquiries. What is the best initial treatment of Parkinson's disease? Schreck J; Kelsberg G; Rich J; Ward R J Fam Pract; 2003 Nov; 52(11):897-9. PubMed ID: 14599387 [No Abstract] [Full Text] [Related]
23. The role of dopamine agonists in the treatment of early Parkinson's disease. Olanow CW Neurology; 2002 Feb; 58(4 Suppl 1):S33-41. PubMed ID: 11909983 [TBL] [Abstract][Full Text] [Related]
24. [Drug therapy of Parkinson's disease]. Myllylä V Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076 [No Abstract] [Full Text] [Related]
28. Early Parkinson's disease: what is the best approach to treatment. Hristova AH; Koller WC Drugs Aging; 2000 Sep; 17(3):165-81. PubMed ID: 11043817 [TBL] [Abstract][Full Text] [Related]
30. Controversies in the therapy of Parkinson's disease. Fahn S Adv Neurol; 1996; 69():477-86. PubMed ID: 8615168 [TBL] [Abstract][Full Text] [Related]
31. The evolution of pharmacological treatment for Parkinson's disease. Almeida QJ; Hyson HC Recent Pat CNS Drug Discov; 2008 Jan; 3(1):50-4. PubMed ID: 18221241 [TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Deleu D; Northway MG; Hanssens Y Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145 [TBL] [Abstract][Full Text] [Related]
35. Current status of selegiline as a neuroprotective agent in Parkinson's disease. Olanow CW; Mytilineou C; Tatton W Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720 [No Abstract] [Full Text] [Related]
36. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. Gerlach M; Desser H; Youdim MB; Riederer P J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458 [TBL] [Abstract][Full Text] [Related]
37. The role of dopamine agonists in early Parkinson's disease. Watts RL Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273 [TBL] [Abstract][Full Text] [Related]
38. [The role of dopaminagonists in the treatment of Parkinson's disease]. Ransmayr G Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084 [TBL] [Abstract][Full Text] [Related]